Key facts
- It has raised $59.6M across 2 recorded rounds; the latest was Early Stage VC ($34.8M) in Mar 2026.
- Consano Bio has filed 2 Form Ds with the SEC since 2025, most recently Mar 2026 ($34.8M sold to 28 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·Watchlist + deal alerts for Consano Bio
Funding rounds
2 roundsAbout Consano Bio
Developer of a biologic therapeutic for orthopedic conditions designed for disease-modifying treatment. The company's platform utilizes an allogeneic multi-protein therapeutic produced via a proprietary scalable manufacturing process that delivers supraphysiological concentrations of plasma and platelet derived cytokines, matrix proteins, and growth factors via targeted epidural injection, modulating the local microenvironment toward inflammation resolution and tissue repair, enabling orthopedic healthcare providers and patients to address the underlying biology of chronic musculoskeletal pain and support regenerative healing alongside clinical disease management.
- Sector
- Healthcare
- HQ
- Burlington, MA, United States
- Founded
- 2022
- Employees
- 9
- Website
- consanobio.com/
- Ownership
- Privately Held (backing)
Consano Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Consano Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Consano Bio in its N-PORT filings yet. We sweep new filings monthly.